Literature DB >> 15741747

Plasma catecholamine levels after fluoxetine treatment in depressive patients.

Patrizia Blardi1, Arianna de Lalla, Alberto Auteri, Sonia Iapichino, Alice Dell'Erba, Paolo Castrogiovanni.   

Abstract

It is known that selective serotonin reuptake inhibitors, widely used as antidepressive drugs, act by inhibiting the cell reuptake of serotonin, but their effect on the catecholaminergic system is not yet completely understood. In this study, we investigated plasma concentrations of norepinephrine, epinephrine and dopamine after acute and chronic administration of fluoxetine in depressive patients. Twelve patients affected by major depression received a single oral dose of fluoxetine in the morning, 5 mg in the first 5 days, 10 mg from the 6th to the 10th day and 20 mg from the 11th to the 40th day. Twelve healthy subjects received a placebo under identical testing procedures. Blood samples were collected at baseline and 7, 10 and 24 h after drug administration on the 1st day of fluoxetine administration at a dose of 5 mg, and on the 1st and the 30th day of fluoxetine administration at a dose of 20 mg (days 11 and 40 of treatment, respectively). We found that plasma norepinephrine, epinephrine and dopamine levels significantly increased after acute and chronic treatment (p < 0.001), reaching the highest concentrations on the last day. No significant changes of these parameters were observed in control patients. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15741747     DOI: 10.1159/000084163

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  8 in total

Review 1.  Mechanisms of hypoglycemia and exercise-associated autonomic dysfunction.

Authors:  Stephen N Davis; Donna Tate; Maka S Hedrington
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

2.  Neuromodulation by soy diets or equol: anti-depressive & anti-obesity-like influences, age- & hormone-dependent effects.

Authors:  Crystal Blake; Kimberly M Fabick; Kenneth Dr Setchell; Trent D Lund; Edwin D Lephart
Journal:  BMC Neurosci       Date:  2011-03-16       Impact factor: 3.288

3.  Propranolol Reverses Impaired Fracture Healing Response Observed With Selective Serotonin Reuptake Inhibitor Treatment.

Authors:  Sooyeon Lee; Lindsey H Remark; Daniel B Buchalter; Anne M Josephson; Madeleine Z Wong; Hannah P Litwa; Rivka Ihejirika; Kevin Leclerc; Danielle Markus; Nury L Yim; Ruchi Tejwani; Vivian Bradaschia-Correa; Philipp Leucht
Journal:  J Bone Miner Res       Date:  2020-01-10       Impact factor: 6.741

4.  The Effects of Tryptophan Enhancement and Depletion on Plasma Catecholamine Levels in Healthy Individuals.

Authors:  Stephen H Boyle; Beverly H Brummett; Cynthia M Kuhn; John C Barefoot; Ilene C Siegler; Redford B Williams; Anastasia Georgiades
Journal:  Psychosom Med       Date:  2019-01       Impact factor: 4.312

5.  Fluoxetine: juvenile pharmacokinetics in a nonhuman primate model.

Authors:  Mari S Golub; Casey E Hogrefe
Journal:  Psychopharmacology (Berl)       Date:  2014-04-04       Impact factor: 4.530

6.  Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect.

Authors:  María José Ortuño; Samuel T Robinson; Prakash Subramanyam; Riccardo Paone; Yung-Yu Huang; X Edward Guo; Henry M Colecraft; J John Mann; Patricia Ducy
Journal:  Nat Med       Date:  2016-09-05       Impact factor: 53.440

7.  Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes.

Authors:  Vanessa J Briscoe; Andrew C Ertl; Donna B Tate; Stephen N Davis
Journal:  Diabetes       Date:  2008-10-03       Impact factor: 9.461

8.  Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals.

Authors:  Vanessa J Briscoe; Andrew C Ertl; Donna B Tate; Sheila Dawling; Stephen N Davis
Journal:  Diabetes       Date:  2008-06-20       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.